INVESTIGADORES
ROMANIN David Emmanuel
artículos
Título:
Impact of Kefir derived Lactobacillus kefiri on the mucosal immune response and gut microbiota
Autor/es:
CARASI, P; RACEDO, S; JACQOT, C; ROMANIN, D; SERRADELL, M; URDACI, M
Revista:
Journal of Immunology Research
Editorial:
Hindawi Publishing Corporation
Referencias:
Lugar: Cairo; Año: 2014
ISSN:
2314-8861
Resumen:
The evaluation of the impact of
probiotics on host health could help to understand how they can be used in the prevention of
diseases. On the basis of our previous studies and in vitro assays on
PBMC and Caco-2 ccl20:luc reporter system presented in this work, the strain Lactobacillus
kefiri CIDCA 8348 was selected and administrated to healthy Swiss mice daily
for 21 days. The probiotic treatment increased IgA in feces
and reduced expression of pro-inflammatory mediators in Peyer Patches
and mesenteric lymph nodes, where it also increased
IL-10. In ileum IL-10, CXCL-1 and mucin 6 genes were up-regulated,
meanwhile in colon mucin 4 was induced whereas IFN-γ, GM-CSF and IL-1β genes
were down-regulated. Moreover, ileum and colon
explants showed the anti-inflammatory effect of L. kefiri since the
LPS-induced increment of IL-6 and GM-CSF levels in control mice was
significantly attenuated in L. kefiri treated mice. Regarding fecal
microbiota, DGGE profiles allowed differentiation of experimental groups in two
separated clusters. Quantitative PCR analysis of different bacterial groups
revealed only significant changes in
Lactobacillus population. In
conclusion, L. kefiri is a good candidate to be used in gut
inflammatory disorders.